Regorafenib plus TAS-102 versus regorafenib alone for advanced bowel cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests whether adding TAS-102 to regorafenib works better than regorafenib by itself for metastatic colorectal cancer after at least one prior treatment has stopped working. It aims to improve how long the cancer can be controlled for patients in later treatment lines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has come back or spread, confirmed by tissue testing
- Your cancer has already tried at least one standard first- or second-line treatment and did not respond or was stopped due to side effects
- You have at least one measurable tumor spot seen on a CT scan
- You are well enough to do usual activities (ECOG performance status 0 to 2) and have at least 12 weeks expected health
- Your blood counts and liver/kidney tests meet required limits from recent screening bloodwork
- You can use effective birth control if you could become pregnant, and you agree to take part
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of regorafenib (a targeted pill that cuts off blood supply to tumors) with a low-dose, continuous chemotherapy regimen for people whose colorectal cancer has spread and is no longer responding to standard treatments. The goal is to see if this mix can slow or stop the cancer's growth.
This trial tests whether adding regorafenib and low-dose aspirin before standard chemotherapy can slow metastatic colorectal cancer after it has progressed on prior treatment. It may help by trying a different cancer-fighting approach earlier, followed by the usual chemo plan.
This Phase 2 study tests whether taking regorafenib alone or with immunotherapy (toripalimab) and a lower-dose radiation plan can better control metastatic colon or rectal cancer that has MSS/pMMR. It may help by combining cancer-blocking medicine with immune activation and focused radiation to metastatic spots.
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
This trial tests a combination of two drugs (cadonilimab plus regorafenib) as a possible third-line option for people with colorectal cancer that has spread to the liver. It is for patients whose cancer is the MSS/pMMR type and who have already tried standard treatments without success.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.